

PTO/SB/02A (08-01)

Substitute for form 1448A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/724,571	
			Filing Date	November 28, 2000	
			First Named Inventor	Anderson	
			Art Unit	1652	
			Examiner Name	Walicka, M. A.	
			Attorney Docket Number	015270-008444US	
Sheet	1	of	4		

U.S. PATENT DOCUMENTS*					
Examiner Initials*	Cite No.†	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code‡ (if known)			
dw	153	6,852,482	02-08-2003	Gurney et al.	
dw	149	6,844,148	01-18-2003	Gurney et al.	
dw	148	6,835,563	12-28-2004	Gurney et al.	
dw	91 B2	6,828,117	12-07-2004	Gurney et al.	
dw	139	6,825,023	11-30-2004	Gurney et al.	
dw	113	6,797,487	09-28-2004	Gurney et al.	
dw	114	6,790,610	09-14-2004	Gurney et al.	
dw	115	6,753,163	06-22-2004	Gurney et al.	
dw	116	6,737,510	05-18-2004	Gurney et al.	
dw	117	6,727,074	04-27-2004	Gurney et al.	
dw	118	6,706,485	03-16-2004	Gurney et al.	
dw	119	6,699,671	03-02-2004	Gurney et al.	
dw	154	6,627,739	09-30-2003	Anderson	
dw	120	6,500,667	12-31-2002	Gurney et al.	
dw	121	6,440,698	08-27-2002	Gurney et al.	
dw	122	6,420,534 ✓	07-16-2002	Gurney et al.	
dw	141	5,863,756	01-26-1999	Barr et al.	
dw	140	2004/0234976	11-25-2004	Gurney et al.	
dw	123	2004/0166507	08-26-2004	Gurney et al.	
dw	124	2004/0048303	03-11-2004	Gurney et al.	
dw	125	2004/0043408	03-04-2004	Gurney et al.	
dw	128	2002/0081634	06-27-2002	Gurney et al.	
dw	130	2002/0037315	03-28-2002	Gurney et al.	
dw	131	2001/0021591	09-13-2001	Gurney et al.	
dw	142	10/817,979		Gurney et al.	
dw	143	10/477,076		Gurney et al.	
dw	144	09/668,314		Gurney et al.	
dw	94	09/548,370		Gurney et al.	
dw	97	09/548,369		Gurney et al.	
dw	95	09/548,365		Gurney et al.	
dw	27	09/404,133		Gurney et al.	
dw	152	60/169,332		Gurney et al.	
dw	28	09/277,229		Citron et al.	
dw	29	60/210,292		Hong et al.	
dw	30	60/178,368		Lin et al.	

Examiner Signature	<i>M. Walicka</i>	Date Considered	4/20/05
--------------------	-------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. †Applicant's unique citation designation number (optional). ‡Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 801.04. §Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ***Applicant is to

PTO/SB/01A (08-03)

Substitute for form 1448A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/724,671	
			Filing Date	November 28, 2000	
			First Named Inventor	Anderson	
			Art Unit	1852	
			Examiner Name	Walicka, M. A.	
			Attorney Docket Number	015270-008444US	
Sheet	2	of	4		

U.S. PATENT DOCUMENTS*						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ³ (if known)			
dm	31	60/177,836			Lin et al.	
dm	32	60/168,060			Lin et al.	
dm	33	60/155,493			Gurney et al.	
dm	34	60/141,363			Lin et al.	
dm	35	60/139,172			Anderson et al.	
dm	36	60/119,571			Basi et al.	
dm	37	60/114,408			Basi et al.	
dm	38	60/101,594			Gurney et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code ²	Number ⁴	Kind Code ⁵ (if known)				
dm	134	WO	01/50829	A2	07-19-2001			<input type="checkbox"/>
dm	135	WO	01/49098	A2	07-12-2001			<input type="checkbox"/>
dm	136	WO	01/49097	A2	07-12-2001			<input type="checkbox"/>
dm	137	WO	01/23533	A2	04-03-2001			<input type="checkbox"/>
dm	170	EP	1 445 263	A1	08-11-2004			<input type="checkbox"/>
dm	171	EP	855 442	A2	07-29-1998			<input type="checkbox"/>
dm	166	GB	2 364 059	B	01-14-2004			<input type="checkbox"/>
dm	167	GB	2 389 114	B	02-04-2004			<input type="checkbox"/>
dm	168	GB	2 389 113	B	02-04-2004			<input type="checkbox"/>
dm	169	GB	2 389 182	B	02-04-2004			<input type="checkbox"/>

Examiner Signature	<i>M. Walicka</i>	Date Considered	4/20/05
-----------------------	-------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with need communication to applicant. *Applicant's unique citation designation number (optional). *Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 801.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.8). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to

PTO/SB/353 (08-03)

Substitute for form 1448B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/724,671	
			Filing Date	November 28, 2000	
			First Named Inventor	Anderson	
			Art Unit	1852	
			Examiner Name	Walicka, M. A.	
Sheet	3	of	4	Attorney Docket Number	016270-006444US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
dw	181	BORK, P., "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle," <u>Genome Research</u> , 10:398-400 (2000).	
dw	179	BROWN et al., "Catalytic Plasticity of Pantoic Acid Modification Enzymes Underlying Chemical Diversity," <u>Science</u> , 282:131-133 (1998).	
dw	178	DAS et al., "Estrogenic responses in estrogen receptor- α deficient mice reveal a distinct estrogen signaling pathway," <u>ENAS</u> , 94:12786-12791 (1997).	
dw	151	Declaration of Michael Bienkowski, Ph.D. in U.S. patent application 09/548,368	
dw	183	DENNIS et al., "Kunitz Domain Inhibitors of Tissue Factor-Factor VIIa," <u>J. Biol. Chem.</u> , 269(35):22129-22136 (1994).	
dw	155	Examination Report for United Kingdom 00121314.9 dated November 1, 2002.	
dw	156	Examination Report for United Kingdom 00121314.9 dated July 21, 2003.	
dw	157	Examination Report for United Kingdom 00121314.9 dated October 30, 2003.	
dw	158	Examination Report for United Kingdom Application 0318112.0 dated November 19, 2003.	
dw	159	Search and Examination Report for United Kingdom Application 0318112.0 dated September 24, 2003.	
dw	160	Search and Examination Report for United Kingdom Application 0318107.0 dated September 25, 2003.	
dw	161	Search and Examination Report for United Kingdom Application 0318113.8 dated September 25, 2003.	
dw	162	Examination Report for United Kingdom Application 0318113.8 dated November 19, 2003.	
dw	163	Examination Report for European Application 00919298.0 dated October 30, 2003.	
dw	164	Search Report for European Application 04006991.6 dated June 11, 2004.	
dw	165	Examination Report for New Zealand Application 534876 dated August 27, 2004.	

Examiner Signature	<i>M. Walicka</i>	Date Considered	04/20/05
--------------------	-------------------	-----------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

60425683 v1

PTO/SB/02B (08-02)

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete If Known		
			Application Number	09/724,571	
			Filing Date	November 28, 2000	
			First Named Inventor	Anderson	
			Art Unit	1652	
			Examiner Name	Walicka, M. A.	
Sheet	4	of	4	Attorney Docket Number	015270-008444US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T #	
dmf	184	International Preliminary Examination Report for PCT application PCT/US00/03819 dated 9/4/02.		
dmf	146	Examination Report for European Application 00919298.0 dated September 9, 2004.		
dmf	147	HARDY, J., "Framing beta-amyloid," <i>Nature Genetics</i> , 1(4):233-234 (1992).		
dmf	176	JACKSON et al., "The p47 ^{phx} Mouse Knock-Out Model of Chronic Granulomatous Disease," <i>J. Exp. Med.</i> , 182:751-758 (1995).		
dmf	182	KICK et al., "Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D," <i>Chem. & Biol.</i> , 4:297-307 (1997).		
dmf	173	KRISTIE, T. M., "The Mouse Homologue of the Human Transcription Factor C/EBP (Cell Factor)," <i>J. Biol. Chem.</i> , 272(42):26749-26755 (1997).		
dmf	174	LI et al., "Cloning and Characterization of Three New Murine Genes Encoding Short Homologues of RNase P RNA," <i>J. Biol. Chem.</i> , 270(42):25281-25285 (1995).		
dmf	150	Office Action dated 5/6/02 in U.S. patent application 09/548,368		
dmf	77	PCT Search report for PCT/US99/20881		
dmf	78	PCT Search report for PCT/US00/03819		
dmf	177	RAABE et al., "Knockout of the abetalipoproteinemia gene in mice: Reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes," <i>PNAS</i> , 95:8686-8691 (1998).		
dmf	172	SUN et al., "Gene Structure, Chromosomal Localization, and Expression of the Murine Homologue of Human Proteinase Inhibitor 6 (PI-6) Suggests Divergence of PI-6 from the Ovalbumin Serpins," <i>J. Biol. Chem.</i> , 270(27): 16089-16096 (1995).		
dmf	175	UMANS et al., "Targeted Inactivation of the Mouse α -Macroglobulin Gene," <i>J. Biol. Chem.</i> , 270(34):19778-19785 (1995).		
dmf	180	VAN DE LOO et al., "An oleate 12-hydroxylase from <i>Ricinus communis</i> L. is a fatty acyl desaturase homolog," <i>ENBS</i> , 92:6743-6747 (1995).		

Examiner Signature	<i>M. Walicka</i>	Date Considered	04/20/05
--------------------	-------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

80425683 v1

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 6

C m p l e if Known

Application Number	09/724,571
Filing Date	November 28, 2000
First Named Inventor	John P. Anderson
Art Unit	1632
Examiner Name	Thaia N. Ton
Attorney Docket Number	015270-006444US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
<i>W</i>	1	6,361,975		03-26-2002	Christie, et al.	
<i>W</i>	2	6,358,725		03-19-2002	Christie, et al.	
<i>W</i>	3	6,319,489		11-20-2001	Powell, et al.	
<i>W</i>	4	6,319,689		11-20-2001	Powell, et al.	
<i>W</i>	5	6,313,268		11-06-2001	Hook	
<i>W</i>	6	6,245,884		06-12-2001	Hook	
<i>W</i>	7	6,245,964		06-12-2001	McConlogue, et al.	
<i>W</i>	8	6,221,645		04-24-2001	Chrysler, et al.	
<i>W</i>	9	6,211,428		04-03-2001	Singh, et al.	
<i>W</i>	10	6,162,630		12-19-2000	Powell, et al.	
<i>W</i>	11	6,025,180		02-15-2000	Powell, et al.	
<i>W</i>	12	5,942,400		08-24-1999	Anderson, et al.	
<i>W</i>	13	5,877,015		03-02-1999	Hardy, et al.	
<i>W</i>	14	5,849,560		12-15-1998	Abraham	
<i>W</i>	15	5,837,672		11-17-1998	Schenk, et al.	
<i>W</i>	16	5,795,963		08-18-1998	Mullan	
<i>W</i>	17	5,766,846		06-16-1998	Schlossmacher, et al.	
<i>W</i>	18	5,750,349		05-12-1998	Suzuki, et al.	
<i>W</i>	19	5,744,346		04-28-1998	Chrysler, et al.	
<i>W</i>	20	5,733,768		03-31-1998	Dixon, et al.	
<i>W</i>	21	5,593,846		01-14-1997	Schenk, et al.	
<i>W</i>	22	5,455,169		10-03-1995	Mullan	
<i>W</i>	23	5,424,205		06-13-1995	Dovey, et al.	
<i>W</i>	112	09/869,414			Gurney, et al.	
<i>W</i>	90	09/794,927			Gurney, et al.	
<i>W</i>	91	09/794,925			Gurney, et al.	

Examiner
Signature

W. K. Linder

Date
Considered

April 12, '03

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 801.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
PA 3269593 v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 6

Complete if Known

Application Number	09/724,571
Filing Date	November 28, 2000
First Named Inventor	John P. Anderson
Art Unit	1632
Examiner Name	Thaia N. Ton
Attorney Docket Number	015270-006444US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	89	09/795,847	NA	Gurney, et al.	
	92	09/794,748		Gurney, et al.	
	88	09/794,743		Gurney, et al.	
	111	09/681,442		Gurney, et al.	
	87	09/551,853		Gurney, et al.	
	96	09/548,376		Gurney, et al.	
	24	09/548,373		Gurney, et al.	
	99	09/548,372		Gurney, et al.	
	94	09/548,370		Gurney, et al.	
	97	09/548,369		Gurney, et al.	
	100	09/548,368		Gurney, et al.	
	98	09/548,367		Gurney, et al.	
	25	09/548,366		Gurney, et al.	
	95	09/548,365		Gurney, et al.	
	26	09/416,901		Gurney, et al.	
	27	09/404,133		Gurney, et al.	
	28	09/277,229		Citron, et al.	
	29	60/210,292		Hong, et al.	
	30	60/178,368		Lin, et al.	
	31	60/177,836		Lin, et al.	
	32	60/168,060		Lin, et al.	
	33	60/155,493		Gurney, et al.	
	34	60/141,363		Lin, et al.	
	35	60/139,172		Anderson, et al.	
	36	60/119,571		Basi, et al.	
	37	60/114,408		Basi, et al.	
	38	60/101,594		Gurney, et al.	

Examiner
Signature*M. A. Lick*Date
Considered

04/12/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for

PA 3269593 v1
Patents, Washington, DC 20231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,571
		Filing Date	November 28, 2000
		First Named Inventor	John P. Anderson
		Art Unit	1632
		Examiner Name	Thaian N. Ton
Sheet 3 of 6	Attorney Docket Number	015270-006444US	

RECEIVED
DEC 11 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
dm	39	EP	EP 0 855 444	A2	07-29-1998			
dm	40	EP	EP 0 848 062	A2	06-17-1998			
dm	48	PCT	WO 01/38487	A2	05-31-2001			
dm	49	PCT	WO 01/36600	A1	05-25-2001			
dm	50	PCT	WO 01/31054	A1	05-03-2001			
dm	51	PCT	WO 01/29563	A1	04-26-2001			
dm	52	PCT	WO 01/00665	A2	01-04-2001			
dm	53	PCT	WO 01/00663	A2	01-04-2001			
dm	47	PCT	WO 00/69262	A1	11-23-2000			
dm	46	PCT	WO 00/68266	A1	11-16-2000			
dm	45	PCT	WO 00/58479	A1	10-05-2000			
dm	44	PCT	WO 00/56871	A2	09-28-2000			
dm	43	PCT	WO 00/47618	A3	08-17-2000			
dm	42	PCT	WO 00/23576	A2	04-27-2000			
dm	41	PCT	WO 00/17369	A2	03-30-2000			
dm	54	PCT	WO 99/64587	A1	12-16-1999			
dm	55	PCT	WO 99/46281	A2	09-16-1999			
dm	57	PCT	WO 99/34004	A2	08-07-1999			
dm	59	PCT	WO 99/31236	A2	06-24-1999			
dm	60	PCT	WO 98/26059		06-18-1998			
dm	61	PCT	WO 98/21589		05-22-1998			
dm	62	PCT	WO 98/13488		04-02-1998			
dm	63	PCT	WO 98/11236		03-19-1998			
dm	103	PCT	WO 97/47314		12-18-1997			
dm	56	PCT	WO 96/40885	A2	12-19-1996			
dm	58	PCT	WO 96/31122	A1	10-10-1996			
dm	102	PCT	WO 96/20725	A2	07-11-1996			

Examiner Signature	<i>dm</i>	Date Considered	04/12/03
--------------------	-----------	-----------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
PA 3269593 v1

→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known	
		Applicati n Number	09/724,571
		Filing Date	November 28, 2000
		First Named Inventor	John P. Anderson
		Art Unit	1632
		Examiner Name	Thaian N. Ton
Sheet 4 of 6	Attorney Docket Number	015270-006444US	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
dm	104	Baldwin, et al., Crystal structures of native and inhibited forms of human cathepsin D: Implications for lysosomal targeting and drug design, <i>PNAS USA</i> , 90:6796-6800 (1993).	
dm	105	Brown, et al., Evaluation of Cathepsins D and G and EC 3.4.24.15 as Candidate β -Secretase Proteases Using Peptide and Amyloid Precursor Protein Substrates, <i>Journal of Neurochemistry</i> , 66: 2436-2445 (1996).	
dm	106	Chevallier, et al., Cathepsin D displays in vitro β -secretase-like specificity, <i>Brain Research</i> , 750:11-19 (1997).	
dm	64	Chyung, et al. Novel β -Secretase Cleavage of β -Amyloid Precursor Protein in the Endoplasmic Reticulum/Intermediate Compartment of NT2N Cells, <i>Journal of Cell Biology</i> , 138: 671-680 (August 11, 1997).	
dm	107	Diedrich, et al., Nucleotide sequence of a cDNA encoding mouse cathepsin D, <i>Nucleic Acids Research</i> , 18:7184 (1990).	
dm	65	Elan Corporation, plc and Pharmacia Corporation announce research collaboration, News 08/09/2000, www.elancorp.com .	
dm	66	Evin, et al., Alzheimer's disease amyloid precursor protein (β APP): proteolytic processing, secretases and β A4 amyloid production, <i>Amyloid; Int. J. Exp. Clin. Invest.</i> 1: 263-280 (September 8, 1994).	
dm	67	Haass, et al., Amyloid β -peptide is Produced by Cultured Cells During Normal Metabolism, <i>Nature</i> , 359: 322-325 (September 24, 1992).	
dm	68	Haass, et al., The Swedish Mutation Causes Early-Onset Alzheimer's Disease by β -Secretase Cleavage Within the Secretory Pathway, <i>Nature Medicine</i> , 12: 1291-1296 (December 1995).	
dm	69	Haass, et al., β -Amyloid Peptide and 3-kDa Fragment are Derived by Distinct Cellular Mechanisms, <i>Journal of Biochemistry</i> , 268: 3021-3024 (February 15, 1993).	
dm	70	Hirosawa, et al., Characterization of cDNA Clones Selected by the GeneMark Analysis from Size-Fractionated cDNA Libraries From Human Brain, <i>DNA Res.</i> , 6(5): 329-336 (October 29, 1999).	

Examiner Signature	<i>Michael</i>	Date Considered	04/12/03
--------------------	----------------	-----------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3269593 v1

→

PTO/SB/03B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,571
		Filing Date	November 28, 2000
		First Named Inventor	John P. Anderson
		Art Unit	1632
		Examiner Name	Thaia N. Ton
		Attorney Docket Number	015270-008444US
Sheet 5 of 6			

RECEIVED

DEC 11 2002

TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
drf	71	Hussain, et al., Identification of a Novel Aspartic Protease (Asp 2) as β -Secretase, <i>Molecular and Cellular Neuroscience</i> , 14: 419-427 (1999).	
drf	72	Kang, et al., The Precursor of Alzheimer's Disease Amyloid A4 Protein Resembles a Cell-Surface Receptor, <i>Nature</i> , 325: 733-736 (February 19, 1987).	
drf	73	Kitaguchi, et al., Novel Precursor of Alzheimer's Disease Amyloid Protein Shows Protease Inhibitory Activity, <i>Nature</i> , 331: 530-532 (February 11, 1988).	
drf	74	Knops, et al., Cell-type and Amyloid Precursor Protein-type Specific Inhibition of A β Release by Bafilomycin A1, a Selective Inhibitor of Vacuolar ATPases, <i>Journal of Biological Chemistry</i> , 270: 2419-2422 (February 10, 1995).	
drf	75	Koo and Squazzo, Evidence that Production and Release of Amyloid β -Protein Involves the Endocytic Pathway, <i>Journal of Biological Chemistry</i> , 269: 17386-17389 (July 1, 1994).	
drf	108	Majer, et al., Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors, <i>Protein Science</i> , 6:1458-1466 (1997).	
drf	76	Mullan, et al., A Pathogenic Mutation for Probable Alzheimer's Disease in the APP Gene at the N-Terminus of β -Amyloid, <i>Nature Genetics</i> 1: 345-347, (August 1992).	
drf	77	PCT Search report for PCT/US99/20881	
drf	78	PCT Search report for PCT/US00/03819	
drf	79	Ponte, et al., A New A4 Amyloid mRNA Contains a Domain Homologous to Serine Proteinase Inhibitors, <i>Nature</i> , 331: 525-527 (February 11, 1988).	
drf	109	Saftig, et al., Amyloidogenic Processing of Human Amyloid Precursor Protein in Hippocampal Neurons Devoid of Cathepsin D, <i>Journal of Biological Chemistry</i> , 271:27241-27244 (1996).	
drf	110	Schechter, et al., On the size of the active site in proteases. I. Papain, <i>Biochemical and Biophysical Research Communications</i> , 27:157-162 (1967).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3269593 v1










Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Applicati n Num b r	09/724,571
		Filing Dat	November 28, 2000
		First Named Inventor	John P. Anderson
		Art Unit	1632
		Examiner Name	Thaian N. Ton
		Attorney Docket Number	015270-006444US
Sheet	6	of	6

RECEIVED

DEC 11 2002

TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	80	Seubert, et al. Secretion of β -amyloid Precursor Protein Cleaved at the Amino Terminus of the β -amyloid Peptide, <i>Nature</i> , 361: 260-263 (January 21, 1993).	
	81	Sinha, et al., Purification and Cloning of Amyloid Precursor Protein β -Secretase from Human Brain, <i>Nature</i> , 402: 537-540 (December, 2 1999).	
	82	Szeesi, The Aspartic Proteases, <i>Scand. J. Clin. Lab. Invest.</i> , 52 (suppl. 210): 5-22 (1992).	
	83	Tanzi, et al., Protease Inhibitor Domain Encoded by an Amyloid Protein Precursor mRNA Associated with Alzheimer's Disease, <i>Nature</i> , 331: 528-530 (February 11, 1988).	
	93	Thompson, et al., Expression and characterization of human β -secretase candidates metalloendopeptidase MP78 and cathepsin D in β APP-overexpressing cells, <i>Molecular Brain Research</i> , 48:206-214. <i>no date</i>	
	84	Vasser, et al., β -secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE, <i>Science</i> , 286 (5440): 735-41 (October 22, 1999).	
	85	Yan, et al., Membrane-anchored Aspartyl Protease with Alzheimer's Disease β -Secretase Activity, <i>Nature</i> , 402: 533-537 (December 2, 1999).	
	101	Young, et al., HIV-1 Protease Inhibitors Based on Hydroxyethylene Dipeptide Isosteres: An Investigation into the Role of the P ₁ -Side Chain on Structure-Activity, <i>J. Med. Chem.</i> , 35:1702-1709 (1992).	
	86	Zhao, et al., β -Secretase Processing of the β -Amyloid Precursor Protein in Transgenic Mice Is Efficient in Neurons but Inefficient in Astrocytes, <i>Journal of Biological Chemistry</i> , 271: 31407-31411 (December 6, 1996).	

Examiner Signature		Date Considered	04/12/03
--------------------	---	-----------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3269593 v1